基于"分子-证候"双维度探讨不同亚型小细胞肺癌的中医精准辨治思路OA

Small cell lung cancer(SCLC)is a highly aggressive neuroendocrine tumor.Currently,the most common subtype classifica-tion of SCLC is mainly based on transcription factors,defined as SCLC-A,SCLC-N,SCLC-P,SCLC-I,and other subtypes.This pa-per systematically constructs,for the first time,the mapping relationship between SCLC molecular subtypes and traditional Chinese med-icine(TCM)syndromes and proposes"molecular-syndrome co-evolution"hypothesis.A precise medication scheme of"syndrome recognition-syndrome differentiation-compound formula"is designed,organically combining SCLC molecular subtyping with TCM syndrome differentiation and treatment.This can,to some extent,overcome the limitations of traditional treatment and provide a new par-adigm for individualized precision therapy.At the same time,it can reveal the biological basis of TCM syndromes at the molecular level(for example,the association of the SCLC-I subtype with the immune microenvironment of"Yin deficiency with internal Heat,defi-ciency of the body's Zheng Qi with lingering Evil Factors"syndrome),breaking through the bottleneck of TCM theory's"abstract-ness".Although this theoretical framework requires further basic research and clinical validation,its integrative thinking is expected to provide certain reference value for tumor treatment.In the future,it is necessary to establish a dynamic correlation model between molec-ular subtypes and TCM syndromes,develop a standardized efficacy evaluation system,and conduct multicenter clinical studies to verify the feasibility of the"molecular-syndrome co-evolution"model based on the dual dimensions of"molecule-syndrome".